Payment overview · 2025
General Payments
$684.61
46 reported records · 9 companies
Healthcare provider profile · identity verified
Steven P Forrest, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MENA, AR · NPI 1194921635
Verified facts
What the public records show
CMS Open Payments records show Steven P Forrest, M.D. received $684.61 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 50.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qulipta, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $344.30 | 50.3% | 30 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $73.35 | 10.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.75 | 8.7% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $58.03 | 8.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.01 | 8.5% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $34.33 | 5.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.13 | 3.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.43 | 2.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.28 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $684.61 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $237.96 | 18 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.51 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.31 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $73.35 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $58.03 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $58.03 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.01 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $4.88 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $4.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 692 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 151 |
| Gabapentin | Gabapentin | 488 | 123 |
| Furosemide | Furosemide | 407 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 356 | 98 |
| Lisinopril | Lisinopril | 348 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 103 |
| Potassium Chloride | Potassium Chloride | 326 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 102 |
| Losartan Potassium | Losartan Potassium | 287 | 80 |
| Tramadol Hcl | Tramadol Hcl | 275 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 259 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 72 |
| Montelukast Sodium | Montelukast Sodium | 237 | 57 |
| Trazodone Hcl | Trazodone Hcl | 230 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 219 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 63 |
| Clonazepam | Clonazepam | 212 | 43 |
| Omeprazole | Omeprazole | 211 | 69 |
| Eliquis | Apixaban | 206 | 52 |
| Spironolactone | Spironolactone | 205 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 193 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 31 |
| Meloxicam | Meloxicam | 151 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 42 |
| Alprazolam | Alprazolam | 145 | 22 |
| Simvastatin | Simvastatin | 140 | 42 |
| Metformin Hcl | Metformin Hcl | 136 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 26 |
| Lorazepam | Lorazepam | 128 | 33 |
| Celecoxib | Celecoxib | 127 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 31 |
| Mounjaro | Tirzepatide | 121 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 29 |
| Famotidine | Famotidine | 115 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 18 |
| Diazepam | Diazepam | 109 | 25 |
| Buspirone Hcl | Buspirone Hcl | 108 | 26 |
| Pregabalin | Pregabalin | 105 | 22 |
| Ondansetron Odt | Ondansetron | 101 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 77 |
| Carvedilol | Carvedilol | 97 | 30 |
| Mirtazapine | Mirtazapine | 97 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 94 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 23 |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Ozempic | Semaglutide | 84 | 13 |
| Baclofen | Baclofen | 82 | 25 |
| Jardiance | Empagliflozin | 79 | 16 |
| Linzess | Linaclotide | 79 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 19 |
| Metformin Hcl Er | Metformin Hcl | 77 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 20 |
| Sucralfate | Sucralfate | 75 | 25 |
| Estradiol | Estradiol | 74 | 20 |
| Finasteride | Finasteride | 73 | 22 |
| Topiramate | Topiramate | 70 | 15 |
| Atenolol | Atenolol | 68 | 24 |
| Clonidine Hcl | Clonidine Hcl | 68 | 32 |
| Farxiga | Dapagliflozin Propanediol | 68 | 18 |
| Donepezil Hcl | Donepezil Hcl | 67 | 19 |
| Prednisone | Prednisone | 67 | 37 |
| Bupropion Xl | Bupropion Hcl | 64 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 15 |
| Allopurinol | Allopurinol | 61 | 20 |
| Fluconazole | Fluconazole | 61 | 35 |
| Methylprednisolone | Methylprednisolone | 61 | 57 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 60 | 12 |
| Cefuroxime | Cefuroxime Axetil | 59 | 50 |
| Meclizine Hcl | Meclizine Hcl | 58 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 14 |
| Temazepam | Temazepam | 57 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 14 |
| Glipizide | Glipizide | 54 | 14 |
| Alendronate Sodium | Alendronate Sodium | 53 | 11 |
| Levetiracetam | Levetiracetam | 53 | 11 |
| Promethazine Hcl | Promethazine Hcl | 53 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 47 |
| Azithromycin | Azithromycin | 52 | 43 |
| Glipizide Er | Glipizide | 50 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 50 | suppressed |
| Naproxen | Naproxen | 50 | 16 |
| Ibuprofen | Ibuprofen | 47 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 16 |
| Memantine Hcl | Memantine Hcl | 46 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 12 |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Glimepiride | Glimepiride | 43 | 11 |
| Propranolol Hcl | Propranolol Hcl | 41 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 13 |
| Valsartan | Valsartan | 38 | 15 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Roflumilast | Roflumilast | 33 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 29 |
| Eszopiclone | Eszopiclone | 29 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Cephalexin | Cephalexin | 27 | 21 |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 21 |
| Mupirocin | Mupirocin | 27 | 20 |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | 11 |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Qulipta | Atogepant | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Otezla | Apremilast | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $684.61 · 46 records | ABBVIE INC. | AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, DALVANCE, EMBLAVEO, JOURNAVX, LYBALVI, Ohtuvayre, QULIPTA, Qelbree, REXULTI, UBRELVY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qulipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error